From November 17 to 20, 2025, MEDICA was successfully held in Düsseldorf, Germany. Led by Mr. Liuwei Zhai, President of Dymind, our international team unveiled the latest innovative solutions and strategic initiatives — including the DH‑88CS[H] Fully Automated Hematology & Immuno‑Glycated Hemoglobin Analyzer and the DH‑8000 Fully Automated Hematology Analysis Line. These advancements showcased Dymind’s AI‑powered diagnostic capabilities, providing enhanced clinical support and embodying our vision that “the simpler, the better.”

The second day began with a vibrant Chinese cultural performance, setting the tone for a series of engaging activities. We were honored to welcome Mr. Taijun Zheng — a Zen traveler whose work beautifully blends traditional Chinese culture with medical innovation — as he shared the captivating art of ink painting with us. Through the subtle interplay of ink and water, his paintings echo Dymind’s visual philosophy and inspire boundless creativity.

Moreover, Mr. Roberto, Senior European Marketing Manager, showcased Dymind’s latest pioneering automated hematology solution — the DH‑88CS[H]. It integrates a unique “5‑in‑1” multi‑parameter detection capability, maximising space efficiency for laboratories. Incorporating advanced four‑dimensional laser scattering technology, DH-88CS[H] ensures exceptional accuracy in white blood cell results. With dye-free PLT‑S detection, it also delivers substantially higher accuracy than traditional PLT detection methods. In addition, its RBC V/HC scattergram assists clinicians in differentiating various types of anemia, providing valuable diagnostic support for more precise patient care.

In the inspiring presentation, Mr. Roberto showcased the product’s unmatched advantages and strong market potential, driven by growing global clinical demand and supported by real‑world data insights. The DH‑88CS[H] sets a new benchmark, redefining the meaning of “Beyond All‑in‑One” for laboratories worldwide.

Dr. Wang, Manager of Dymind’s Medical Academic Department, shared groundbreaking insights into "AI‑Driven Routine Blood Analysis for Research and Clinical Applications", unveiling the blueprint for Dymind’s next-generation AI diagnostic ecosystem. 

From advanced testing data analysis to intelligent clinical decision support, we are committed to expanding our portfolio of disease early-screening solutions — spreading China’s innovation to help drive the global transformation toward digital and intelligent healthcare.

In addition to the on-site activities, Dymind’s booth showcased a diverse range of innovative product lines. For instance, the CA1200 coagulation solution, equipped with integrated optical-magnetic technology and an “N+1” reagent solution, strikes an ideal balance between testing cost and quality; The DP-H50 series portable multifunctional analyzers integrate hematology, fluorescence, colloidal gold and dry chemistry technologies — meeting laboratory professionals’ needs for comprehensive multi-item testing. These multi-matrix innovations received enthusiastic praise from experts and scholars attending the event, and also drew strong interest from industry peers and potential partners, highlighting Dymind’s commitment to driving technological advancement and delivering greater value to global laboratories and hospitals.

From flagship AI-powered innovations to strategic partnerships across localized clinical systems, Dymind is on a continuous journey toward professional excellence and intelligent discovery. Moving forward, we welcome new collaborations to explore shared opportunities and to shape a healthier, smarter future together.